In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The FDA’s Oncologic Drugs Advisory Committee has voted against the benefit/risk profile of GSK’s Blenrep just days before the drug’s PDUFA date.

3M raised its full-year earnings outlook after beating expectations in the second quarter. American Express posted higher revenue in the second quarter, driven by a 20% jump in card fees. The company ...

The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for treatment in 133 countries.

Dr Reddy's Laboratories Ltd.'s formulations manufacturing facility was given "Form 483" with seven observations from the ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

The agreement, signed Monday between CMS and DHS, has not been announced publicly, AP reports. Other Trump administration news is on gender-affirming care for youth, President Donald Trump's vein ...

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

London’s FTSE 100 was up 0.2% at 8,986.82 in afternoon trade on Friday. BP was in the black as the oil giant agreed to sell ...